In CY2013, the Indian Contract Research and Manufacturing Services (CRAMS) industry was estimated to be worth ~US$7.6-7.8bn. Its dominant segment, Contract Manufacturing Services (CMS), was estimated to account for ~60% of the industry revenue; and Contract Research Services (CRS) ~40%. CARE Research expects the domestic CRAMS industry to grow at robust rate from CY2014-2018. The Indian CRAMS industry is likely to benefit from lower manufacturing costs, rising cost of research in developed markets and increase in number of drugs going off-patent. These conditions are expected to result in increasing outsourcing of pharmaceutical manufacturing and research. Indian players are preferred over other low-cost manufacturing geographies due to the largely generic mix of the Indian pharma industry. Additionally, India benefits from availability of English-speaking, low-cost, highly-skilled professionals. The report on 'Indian CRAMS Industry' evaluates the industry scenario and presents its outlook based on past performance and the evolving dynamic in the industry. It also focuses on the growth drivers, pharma industry and player analysis.
To receive CARE Research publications and alerts.